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Abstract 
Introduction: Docetaxel is a chemotherapy drug widely prescribed in oncology that recognizes a variety of manu-
factured generics whose toxicity is increasingly reported. The aim of this study was to compare the toxicities between 
the original and a generics docetaxel in a Moroccan center.
Methods: In a cross sectional study, we enrolled patients treated with docetaxel from the oncology department of 
the military hospital of Rabat over a period of 2 years (2013–2014). We compared the prevalence of hypersensitiv-
ity reactions, febrile neutropenia, peripheral neuropathy, gastrointestinal, cutaneous, and hematologic toxicities, 
between four different presentations of docetaxel including the original drug. Only grade II or worse adverse events 
related to chemotherapy were considered. Treatments discontinuations due to toxicity were also compared. Unusual 
skin toxicities were included.
Results: 81 patients were eligible for analysis [43/generics arm vs. 38/original drug arm. Hematological toxicity was 
significantly more frequent in the generic arm than in the original drug (32.6 vs. 13.2 %; p = 0.04)]. Also, a signifying 
higher rate of treatment discontinuation was observed in the generic arm (39.5 vs. 7.9 %, p = 0.001). The use of spe-
cific generic increase numerically the skin toxicities (17.6 vs. 0 %, p = 0.026).
Conclusion: Our data suggest that generics of docetaxel are associated with an increase of hematological and cuta-
neous toxicities, an increase of treatment discontinuation rate and emphasize the need of a regulation of generics’ 
manufacture.
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Background
Docetaxel is a second-generation taxane that produces a 
cytotoxic effect by inhibiting depolymerization of micro-
tubules which, in turn, inhibits cell replication. This drug 
has also been shown to inhibit angiogenesis, induce 
signaling aberrations, and induce mitotic catastrophe or 
apoptosis (Herbst and Khuri 2003). Docetaxel was devel-
oped by sanofi-aventis and is registered and marketed in 
the form of an injectable solution under the brand name 
Taxotere*. It is highly effective as monotherapy and com-
bination therapy across a variety of tumor types includ-
ing breast cancer in its various stages, non-small cell 
lung cancer, androgen-independent metastatic prostate 
cancer, head and neck cancers, gastric cancer and other 
indications except approval (Sanofi-Aventis U.S. LLC 
2011). The most common severe adverse reactions (grade 
III–IV) related to docetaxel (100 mg/m2) as a single agent 
are asthenia (12.8  %), cutaneous reactions (4.8  %), fluid 
retention (6.9  %), gastrointestinal reactions (2.7–4.7  %), 
hypersensitivity reactions (4.2 %), neurosensory reactions 
(4.3 %), neuromotor reactions (3.6 %), stomatitis (5.5 %), 
anemia (8.8  %), febrile neutropenia (11.0  %), infections 
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(6.1  %), leucopenia (31.6  %), and neutropenia (75.4  %) 
(Sanofi-Aventis U.S. LLC 2011).
Due to its multiple indications, docetaxel recognizes 
a variety of generic used to modulate the economic cost 
(Generic Pharmaceutical Association 2009). Generic 
drugs are a huge and complex part of the health-care 
market. Cancer drugs are no exception. In a total global 
oncology drugs market approaching $100 billion, rev-
enues from generics are growing at twice the rate of 
the market as a whole, the vast majority of all drug pre-
scriptions are already for generics more than 80 % in the 
United States, for example Generic Pharmaceutical Asso-
ciation (2009).
To obtain Moroccan approval (Décret n° 2-12-198 du 
21 rejeb 1433, 2012), a generic drug must prove phar-
maceutical properties equivalent to those of a reference 
drug in terms of efficacy and safety. This bioequivalence 
recommended the same amount of active ingredient, in 
the same dosage and using the identic route of admin-
istration, and comply with accepted standards of qual-
ity, purity in accordance with international guidelines 
(Food and Drug Administration 2012). However; phase 
IV post-marketing studies were not required to have 
approbation.
Differences in generic drug formulations have been 
noted, and probably have an impact on drugs with a nar-
row therapeutic index as a docetaxel. Toxicity of generic 
docetaxel is increasingly reported in the literature and is 
a subject of heated debate and controversy. Impurities, 
excipients, and the amount of active agent itself can all 
have an impact on the efficacy and have been implicated 
in the occurrence of these side-effects (Vial et  al. 2008; 
Garrido-Siles et al. 2015).
Also, following the introduction of these new formula-
tions of docetaxel, our oncology department recorded a 
higher prevalence of differents toxicities reported with 
atypical symptomatology and pronounced grades causing 
an imbalance of cost/benefit. The aim of this study was to 
assess the frequency of grade II, III and IV adverse events 
and discontinuation treatment due to toxicity between 
original docetaxel and a generics formulation in a Moroc-
can department of medical oncology.
Methods
Study design
This is a retrospective study over a period of 2  years 
(from 1 January 2013 to 31 December 2014) including 
patients who were treated with docetaxel at the medical 
oncology department of the military hospital in Rabat in 
Morocco. Patients were assigned into 4 groups. Group 1 
receiving original drug, group 2 receiving the first generic 
(French origin), group 3 receiving the second generic 
(Australian-American origin) and group 4 receiving the 
third generic (Indian origin). We compare the incidence 
of hypersensitivity reactions, gastrointestinal, cutaneous, 
hematological toxicities, febrile neutropenia and periph-
eral sensory neuropathy to four different presentations 
of docetaxel including the original drug. Only grade II or 
worse adverse events related to chemotherapy should be 
considered according to the classification NCI CTCAE 
4.0 (national cancer institute common terminology cri-
teria for adverse events) (U.S. Department of Health and 
Human Services 2009). Treatment discontinuation due to 
toxicity is also compared. Unusual skin toxicities with are 
included. Toxicities grade III or worse were declared to 
the national pharmacovigilance Centre.
Hypersensitivity reactions were categorized according 
to CTCAE 4.0 criteria, considering as an event any grade 
II or more allergic reaction, requiring immediate discon-
tinuation of the infusion of docetaxel and appropriate 
treatment to counteract the reaction.
Hematologic toxicities include anemia with hemo-
globin less than 10.0 g/dL, neutropenia with neutrophils 
less than 1500  cells/mm3, leukopenia with white blood 
cells less than 4000  cells/mm3, and thrombocytopenia 
with platelets less than 100,000 cells/mm3.
Febrile neutropenia was defined by neutrophils less 
than 1000/mm3 with a single temperature of >38.3 °C or a 
sustained temperature of ≥38 °C for more than 1 h.
Patients treated with TPF Protocol have benefited from 
a pegfilgrastim primary prophylaxis from days 5 to 11 
whatever the drug used.
Gastrointestinal toxicities include nausea, vomiting 
more than two episodes in 24 h, and diarrhea increase of 
four stools per day.
Peripheral sensory neuropathy was defined by symp-
toms limiting instrumental or self care of activity daily 
living.
Skin toxicity include hand and foot syndrome limiting 
instrumental or self care of activity daily living.
Unusual skin toxicities are defined as being toxicities 
related to the use of chemotherapy that are not described 
in the monograph of the original drug like localized ery-
thema of the extremities (palm of the hands and soles of 
the feet) with edema, followed by desquamation.
Patients routinely receive premedication with oral 
corticosteroids started 1  day before chemotherapy and 
maintained 3 days after (prednisolone 1 mg per kg), with 
intravenous infusion on the day of chemotherapy (meth-
ylprednisolone 120 mg bolus 30 min before docetaxel).
Excluded patients are those that have less than grade 
II toxicity. Other reasons for exclusion included the 
absence of premedication and patients in which the mol-
ecule used was not mentioned.
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Data collection
Informations on demographic characteristics and medi-
cal history were collected using the clinical files in all 
cases with determination of the age, sex, cancer diag-
nosis, chemotherapy protocol, number of courses, drug 
involved and type of toxicity. Unusual skin toxicities are 
retained after a dermatological consultation confirming 
the responsibility of drugs used and eliminating other 
possible causes.
Statistical analysis
All analyses were performed with SPSS 18 software. The 
number of patients and the corresponding percentages 
were given for categorical variables, mean  ±  standard 
deviation were reported to describe the normally distrib-
uted continuous variables, and medians with interquar-
tile ranges were reported for continuous variables with 
skewed distributions. The Kolmogorov–Smirnov test was 
performed on all measures to assess data normality. Chi 
square or Fisher’s exact test were used to compare the 
categorical variables as appropriate. Means were com-
pared using the Student’s  t-test and medians were com-
pared using the Mann–whitney test. Univariate logistic 
regression analysis was conducted to compare several 
toxicities between the original drug and generics. A p 
value <0.05 was considered statistically significant.
Results
During the period of this study, 282 courses of chemo-
therapy docetaxel were administered to 81 patients. 38 
have received the original drug and 43 patients received 
one of three presentations of generics, 15 patients 
received the first generic, 17 patients received the sec-
ond generic), and 11 patients received the third generic. 
The mean age of the patients was 48.3 ± 9.2 years with 
a female predominance (79  %). Baseline characteristics 
of patients are summarized in Table  1. The most fre-
quent diagnosis was breast cancer (79  %), and the fol-
lowing chemotherapy regimens were most commonly 
used: 5FU-epirubicin-cyclophosphamide (three cycles) 
followed by docetaxel (three cycles) (3FEC100-3taxotere 
scheme) (54.3  %), docetaxel–trastuzumab combination 
(12.4 %), and docetaxel monotherapy (28.4 %).
Table  2 shows the comparative analysis of toxicities 
observed in both arms. 
Toxicities of each formulation were evaluated in com-
parison with the original drug in the Tables 3, 4 and 5. 
The hematologic toxicity was more frequent in the 
generic arm than in the original drug (32.6 vs. 13.2  %, 
p = 0.04). Furthermore, higher rate of treatment discon-
tinuation was observed in the generic group with a rate 
of 39.5  % versus 7.9  % in the original drug (p =  0.001) 
(Table 2).
In univariate analysis, hematologic toxicity (OR 3.18 
95  % IC [1.02; 9.92]; p  =  0.046) and treatment discon-
tinuation (OR 7.62 95 % IC [2.02; 28.78]; p = 0.003) were 
significantly associated with the generics’ use (Table 6).
In subgroups analysis, only the third generic was sig-
nificantly associated with an increase of hematological 
toxicities (63.6 vs. 13.2 %; p = 0.002) and treatment dis-
continuation (72.7 vs. 7.9 %; p < 0.001) (Table 5).
No leukopenia or neutropenia has been reported in 
patients who received pegfilgrastim primary prophylaxis. 
The use of this prophylaxis did not influence the results 
obtained [2.67 % in the original group versus 7 % in the 
generic group, p = 0.61(Table 1)].
A grade II immediate hypersensitivity reaction 
occurred in one patient during infusion of the first course 
of docetaxel (original drug) requiring discontinuation 
treatment (Table  2). The symptoms reported were skin 
rash, flushing, tachycardia, dizziness and hypotension. 
Outcome was favorable after fluid replacement, intra-
venous paracetamol, corticosteroid and hydroxyzine. 
Retreatment with docetaxel was well tolerated after 
decreasing the infusion rate.
No skin toxicity was observed in patients treated by 
original drug (Table  2). However, severe hand foot syn-
drome grade III was observed in three patients of generic 
group requiring discontinuation treatment (Fig.  1). 
Moreover, two patients of the same group have developed 
unusual skin toxicities: extra nail hypermelanosis sitting 
in the abdominal wall evolving favorably after corticos-
teroids and antihistamines medication in a patient, and 
ichthyosis-like eruption of the lower limbs in the other 
(Fig. 2). Cutaneous toxicities were significantly more fre-
quent in patients treated by the second generic compared 
to the original drug (17.6 vs. 0 %; p = 0.026) (Table 4).
Discussion
Our study shows an increase of hematological toxicities, 
skin toxicities, and increase of treatment discontinuation 
rate especially with two of three generics used. There are 
few studies in the literature that have investigated the tox-
icity of the docetaxel’s generics. Siles-Garrido et al. report a 
significant increase in the incidence of acute infusion reac-
tions and unusual irritative skin toxicity in patients treated 
with three formulations of docetaxel (Garrido-Siles et  al. 
2015). Skin lesions observed in this study appear early, 
with a purplish red inflammatory character, painful and 
perivenous topography adjacent to the drug administra-
tion site. These lesions were similar to extravasation with 
a less favorable response to corticosteroids. This toxicity 
was seen in 9 % of patients, including 1.5 % who required 
dose adjustment. In our series, no acute infusion reactions 
have been reported with generics drugs. However, skin 
toxicity was seen in 11.5  % of cases with predominance 
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of hand-foot syndrome grade III. Also, two unusual skin 
toxicities were observed: extra nail hypermelanosis and 
ichthyosis-like eruption. The incidence of grade III/IV 
skin toxicities described for original drug varies from 0.8 
to 5.9  % depending on the dose used (Chew and Chuen 
2009). Elementary lesions are erythematous maculopapu-
lar rash on the extremities, face, chest and arms.
A recent retrospective study carried out in Canada 
compared just one generic (second generic in our study) 
with the original in 364 patients with breast cancer found 
no difference between groups for occurrence of intes-
tinal perforations, thrombotic events, hand and foot 
syndromes, and docetaxel-related deaths. The num-
ber of febrile neutropenic events was similar in both 
groups (original, 17.6  %, vs. generic, 18.1  %; p  =  0.89 
and p = 0.71 after adjustment for context, use of G-CSF 
(granulocyte colony-stimulating factor), docetaxel dose, 
and age, using a Poisson model. However, the proportion 
Table 1 Patients’ baseline characteristics
T taxotere, FEC 5-fluorouracil + epirubicin + cyclophosphamide, TH docetaxel + trastuzumab, TPF docetaxel + cisplatin + 5-fluorouracil
a Mean ± standard deviation











Age (ans)a 46.2 ± 8.2 48.5 ± 8.7 53 ± 10.7 48.1 ± 9.2 48.3 ± 9.2
Sex
 Male 6 (15.8 %) 2 (13.3 %) 7 (41.2 %) 2 (18.2 %) 17 (21 %)
 Female 32 (84.2 %) 13 (86.7 %) 10 (58.8 %) 9 (81.8 %) 64 (79 %)
Cancer diagnosis
 Early breast 26 (68.4 %) 9 (60 %) 9 (52.9 %) 8 (72.7 %) 52 (64.2 %)
 Metastatic breast 6 (15.8 %) 4 (26.7 %) 1 (5.9 %) 1 (9.1 %) 12 (14.8 %)
 Gastric 2 (5.3 %) 0 2 (11.8 %) 0 4 (4.9 %)
 Head and neck 1 (2.6 %) 2 (13.3 %) 1 (5.9 %) 0 4 (4.9 %)
 Lung 1 (2.6 %) 0 2 (11.8 %) 0 3 (3.7 %)
 Prostate 2 (5.3 %) 0 2 (11.8 %) 1 (9.1 %) 5 (6.2 %)
 Sarcoma 0 (0 %) 0 0 1 (9.1 %) 1 (1.2 %)
Chemotherapy protocol
 T 9 (23.7 %) 4 (26.7 %) 7 (41.2 %) 3 (27.3 %) 23 (28.4 %)
 FEC-T 22 (57.9 %) 7 (46.7 %) 8 (47.1 %) 7 (63.6 %) 44 (54.3 %)
 FEC-TH 4 (10.5 %) 2 (13.3 %) 1 (5.9 %) 1 (9.1 %) 8 (9.9 %)
 TPF 1 (2.6 %) 2 (13.3 %) 1 (5.9 %) 0 4 (4.9 %)
 TH 2 (5.3 %) 0 0 0 2 (2.5 %)
Number of chemotherapy coursesb 3 [3, 5] 3 [2, 3] 3 [3, 4.5] 3 [2, 3] 3 [3, 4]
Table 2 Comparative analysis of the toxicity of docetaxel: 
original drug versus generics
Italic values indicate statistical significants





Hypersensitivity 1 (2.6 %) 0 (0 %) 0.46
Peripheral sensory neuropathy 2 (5.3 %) 7 (16.3 %) 0.16
Hematological toxicities 5 (13.2 %) 14 (32.6 %) 0.04
Febrile neutropenia 1 (2.6 %) 4 (9.3 %) 0.36
Gastrointestinal toxicity 2 (5.3 %) 6 (14 %) 0.27
Skin toxicity 0 (0 %) 5 (11.6 %) 0.05
Extra nail hypermelanosis 0 (0 %) 1 (2.3 %) 1
Hand foot syndrome grade III 0 (0 %) 3 (7 %) 0.24
Ichthyosis-like eruption 0 (0 %) 1 (2.3 %) 1
Treatment discontinuation 3 (7.9 %) 17 (39.5 %) 0.001







Hypersensitivity 1 (2.6 %) 0 (0 %) 1
Peripheral sensory neuropathy 2 (5.3 %) 2 (13.3 %) 0.56
Hematological toxicities 5 (13.2 %) 3 (20 %) 0.67
Febrile neutropenia 1 (2.6 %) 1 (6.7 %) 0.49
Gastrointestinal toxicity 2 (5.3 %) 2 (13.3 %) 0.56
Skin toxicity (hand foot  
syndrome grade III)
0 (0 %) 1 (6.7 %) 0.28
Treatment discontinuation 3 (7.9 %) 4 (26.7 %) 0.09
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of grade IV febrile neutropenia was higher in the generic 
group (original, 56.3 %, vs. generic, 78.8 %; p = 0.05 and 
p = 0.06 after adjustment for context, use of G-CSF, doc-
etaxel dose, and age, using a Poisson model (Poirier et al. 
2014).
Two factors could contribute to the explanation of 
these equivalent results: firstly, the present study may suf-
fer from some certain weaknesses that make patients in 
the generic arm received more growth factors, and then 
this drug is likely to be of high quality, given it is on the 
Canadian market, which is said to have one of the world’s 
best bio-equivalence inspection regimes. However, 
patients who received this generic needed prolonged 
hospitalization and increased use of granulocyte growth 
factors, suggesting the loss of the economic benefit to use 
generic drugs (Poirier et al. 2014).
Several theories have attempted to explain the tox-
icities with generic docetaxel based on pharmacological 
characteristics. The mechanisms involved were under-
dosing docetaxel, high level of impurities and excipients 
used.
Levels of docetaxel were evaluated by Vial et  al. on 
generic formulations purchased in 14 countries (Vial 
et  al. 2008). The results were surprising 21 generics 
Table 4 Comparative analysis of  toxicity: original drug 
versus generic no. 2






Hypersensitivity 1 (2.6 %) 0 (0 %) 1
Peripheral sensory neuropathy 2 (5.3 %) 2 (11.8 %) 0.58
Hematological toxicities 5 (13.2 %) 4 (23.5 %) 0.43
Febrile neutropenia 1 (2.6 %) 1 (5.9 %) 0.52
Gastrointestinal toxicity 2 (5.3 %) 3 (17.6 %) 0.16
Skin toxicity 0 (0 %) 3 (17.6 %) 0.026
Hand foot syndrome grade III 0 (0 %) 2 (11.8 %) 0.09
Ichthyosis-like eruption 0 (0 %) 1 (5.9 %) 0.3
Treatment discontinuation 3 (7.9 %) 5 (29.4 %) 0.09
Table 5 Comparative analysis of  toxicity: original drug 
versus generic no. 3






Hypersensitivity 1 (2.6 %) 0 (0 %) 1
Peripheral sensory neuropathy 2 (5.3 %) 3 (27.3 %) 0.06
Hematological toxicities 5 (13.2 %) 7 (63.6 %) 0.002
Febrile neutropenia 1 (2.6 %) 2 (18.2 %) 0.12
Gastrointestinal toxicity 2 (5.3 %) 1 (9.1 %) 0.54
Skin toxicity (extra nail hyper-
melanosis)
0 (0 %) 1 (9.1 %) 0.22
Treatment discontinuation 3 (7.9 %) 8 (72.7 %) <0.001
Table 6 Simple logistic regression examining the toxicities 
associated with generics
Italic values indicate statistical significants
Univariate analysis
OR IC 95 % p
Peripheral sensory neuropathy 3.5 0.68, 18 0.13
Hematological toxicities 3.18 1.02, 9.92 0.046
Febrile neutropenia 3.8 0.4, 35.54 0.24
Gastrointestinal toxicity 2.9 0.55, 15.42 0.2
Treatment discontinuation 7.62 2.02, 28.78 0.003
Fig. 1 Hand foot syndrome grade III in a patient prescribed generic 
drug formulation 3
Fig. 2 Ichthyosis-like eruption of the lower limbs in a patient pre-
scribed generic drug formulation 2
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contained less than 90 % docetaxel, 11 of which had less 
than 80  % of what would be expected. Only 10 were in 
the acceptable range of 90–110  %. In referring to this 
study, the first and third generics used in our study were 
away the acceptable range. The second generic was not 
available at the time of the study.
Levels of impurities were also obtained in same study 
using reverse-phase liquid chromatography with ultravi-
olet detection setting a conservative limit of 3 % (the ref-
erence was 1.6 %). They found that 23 of the generics had 
impurities levels of more than 3 % and one of the gener-
ics, from India, had a 20  % level of impurities. Impor-
tantly, 33 of the impurities were not detected at all in the 
reference which that we do not know the physiological 
role and clinical consequences. In our study, the first and 
the third generic employed have high levels impurities 
(which one had a more than 6 %).
The role of excipients is also reported, docetaxel is a 
hydrophobic drug that requires solvents to improve its 
solubility and allow its constitution. The solubiliser used 
is polysorbate 80 (Tween 80), a non-ionic surfactant 
vehicle whose main constituent is polyoxyethylene-
20-sorbitanmonooleate which is structurally equivalent to 
polyethylene glycols (PEG). Nevertheles, polysorbate 80 is 
a pharmacologically and biologically active excipient asso-
ciated with side effects such as hypersensitivity reactions, 
peripheral neuropathy (Tije et al. 2003), vascular toxicity 
and fluid retention (Drori et al. 1995; Mark et al. 2001).
The other excipient mostly described in the literature is 
ethanol, a substance whose presence must be indicated on 
the drug that contains it. Cases of alcohol poisoning have 
been reported in patients receiving high doses of ethanol 
or in pediatric population, who are more susceptible to 
the effects of this substance (Zuccotti and Fabiano 2011). 
The food and drug administration (FDA) is warning that 
the chemotherapy drug docetaxel contain ethanol, also 
known as alcohol, which may cause patients to experience 
intoxication or feel drunk during and after treatment (U.S. 
Food and Drug Administration 2014). The warning was 
issued after a review of the FDA database and the data in 
the medical literature about adverse effects, which iden-
tified three cases of alcohol intoxication associated with 
various presentations of docetaxel (Mirza and Mithal 
2011). Two incidents occurred during the infusion; one 
patient developed symptoms within 24 h.
Eight formulations of docetaxel have been identified 
by the FDA including generic and brand-name products, 
from several manufacturers. The alcohol content in each 
200-mg dose ranges from a low of 2 g in original drug to 
a high of 6.4 grams in docetaxel injections manufactured 
by Pfizer (U.S. Food and Drug Administration 2014).
In Australia, Pfizer’s docetaxel application was with-
drawn before a final decision by the country’s regulator. 
In contrast, the United Kingdom, and the United States 
have both authorized this generic.
The alcohol content in a dose of docetaxel may affect the 
central nervous system and should be taken into account 
for patients in whom alcohol intake should be avoided or 
minimized, including patients with hepatic impairment. 
Docetaxel formulation with the lowest possible alcohol 
content should be considered for patients who experience 
adverse reactions (U.S. Food and Drug Administration 
2014). Patient may also have religious objections.
Clinically, the Garrido-Siles study (2015) suggested that 
some skin toxicities of docetaxel may be caused by the 
excipients used in the different generics. There seems to 
be a relationship between the lower content of polysorb-
ate 80 and the lower incidence of severe hypersensitivity 
reactions. However, administration of presentations with 
higher ethanol content is associated with increased inci-
dence of skin toxicity, occasionally severe, near the injec-
tion site of the drug.
There was also a significant increase in the incidence of 
skin toxicity following the administration of the second 
generic (17.6 vs. 0 %; p = 0.026). New cutaneous toxici-
ties with generic docetaxel were observed, but relation-
ship with content of ethanol or polysorbate 80 was not 
assessed.
While the results of the study are statistically signifi-
cant, it is premature to make definitive conclusions on 
the quality of generic docetaxel from various sources. 
Nevertheless, the data are supportive of other studies 
suggesting that the formulation of generic docetaxel is 
important to consider, as some appear to be increasing 
host toxicity in a vulnerable patient population.
The present study has some methodological weak-
nesses. They are the small sample size and the retrospec-
tive nature of the study, including heterogeneous baseline 
demographic and disease characteristics. These include 
age, sex, stage, disease site and comorbidities which 
could have induced bias in the case selection or events 
reporting. Moreover, different chemotherapy regimens 
and generics were used, with unavailability of informa-
tion on levels of impurities, levels of docetaxel and the 
excipients used. These factors should be considered in 
future studies.
Conclusion
Our data suggest that generics of docetaxel are associated 
with an increase of hematological toxicities, cutaneous 
toxicities, and an increase of treatment discontinuation 
rate for which the exact mechanism is unknown. Seri-
ous adverse events, requires longer hospitalization and 
the economic benefit of using a generic formulation may 
be lost. So, therapeutic changes could impact the over-
all survival of patients. International harmonization of 
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regulations in the manufacture of generics should be 
encouraged.
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